Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To evaluate by modelling the economic benefits of left ventricular hypertrophy (LVH) regression in patients with arterial hypertension (HT) due to therapy with fixed combination of valsartan/amlodipine.  Material and methods. 20 patients (15 females and 5 males, aged 18 to 70 years) with essential HT accompanied by metabolic syndrome with a history of previous ineffective antihypertensive therapy were included into the study. All patients were treated with fixed combination of amlodipine/valsartan in doses of 5/160 and 10/160 mg depending on blood pressure (BP) level. Treatment duration was 24 weeks. Changes in BP level, LVH regression were assessed. Economic evaluation was performed on the basis of modelling with the specialized software Decision Tree 4.xla. Results. Effect of fixed amlodipine/valsartan combination therapy on LVH was used to estimate treatment effectiveness and to build the model. Patients were distributed according to left ventricular (LV) mass (at baseline and after 24 weeks of therapy). Significant decrease in LV mass from 205.8±50.4 to 181.9±45.1 g (p<0.05) was revealed. The model took into account economic and frequency factors for 10 year prognosis: this therapy prevents 36 deaths, 6 strokes, 24 myocardial infarction per 1000 patients. Absence of need in treatment of these prevented events can save 2 516 772.42 RUR for every 1 000 patients. It would reduce the total costs per patient during 10 years. Conclusion. Treatment with amlodipine/valsartan single pill combination has not only clinical advantages, but also pharmacoeconomic benefits. This combination reduces risk of acute myocardial infarction and death more effectively. Treatment with fixed valsartan/amlodipine combination saves maximum years of life with less cost during 10 years. Despite of higher pharmacotherapy costs, fixed valsartan/amlodipine combination reduces total costs due to prevention of fatal and nonfatal cardiovascular events.

About the Authors

E. I. Tarlovskaya
Kirov State Medical Academy
Russian Federation

N. S. Maksimchuk
Kirov State Medical Academy
Russian Federation

S. V. Malchicova
Kirov State Medical Academy
Russian Federation

M. V. Avksentieva
Russian National Research University named after N.I. Pirogov
Russian Federation

I. E. Sapozhnikova
Kirov State Medical Academy
Russian Federation

Y. A. Balandina
Kirov State Medical Academy
Russian Federation


1. Giljarevskij S.R. Clinical effectiveness and cost-effectiveness of combination treatments with fixed-dose ACE inhibitor and thiazide diuretic. Farmateka 2005;10: 27-35. Russian (Гиляревский С.Р. Клиническая эффективность и экономическая целесообразность применения комбинированных препаратов с фиксированными дозами ингибитора ангиотензин-превращающего фермента и тиазидного диуретика. Фарматека 2005;10: 27-35).

2. Ostroumova O.D., Nedogoda S.V., Mamaev V.I., Shorikova E.G. Pharmacoeconomic aspects of the effectiveness of inhibitors of the enzyme angiotenziprevraschayuschego in hypertension and heart failure. Russkij medicinskij zhurnal 2003; 11(5): 262-266. Russian (Остроумова О.Д., Недогода С.В., Мамаев В.И., Шорикова Е.Г. Фармакоэкономические аспекты эффективности ингибиторов ангиотензин-превращающего фермента при артериальной гипертонии и сердечной недостаточности. Русский медицинский журнал 2003; 11(5): 262-266).

3. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.doi: 10.1136/bmj.b1665.

4. Leonova M.V., Erofeeva S.B., Bykov A.V., Belousov Iu.B. Pharmacoeconomic analysis of antihypertensive therapy: advantages of fixed combinations. Kardiologiia 2008;48(1):43-50. Russian Леонова М.В., Ерофеева С.Б., Быков А.В., Белоусов Ю.Б. Фармакоэкономический анализ антигипертензивной терапии: преимущества фиксированных комбинаций. Кардиология 2008; 1: 43-50.

5. Massie B.M. Analyses of cost effectiveness in the management of essential hypertension: what they can and what they do not teach us. Clin Cardiol 1996; l9(Suppl.l0): 810-816.

6. Fischer M.A., Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004; 291(15):1850-6.

7. Tarride J.-E., Morgan L., DesMeules M. et al. A review of the cost of cardiovascular disease. The Canadian journal of cardiology 2009; 25(6): 195-202.

8. Elisaf M., Liberopoulos E.N. Are the pleiotropic effects of drugs used for the prevention of cardiovascular disease clinically relevant? Curr Pharm Des 2009; 15(5):463-466.

9. Koren M.J., Savaage D.D., Casale P.N. Changes in left ventricular mass predict risk in essential hypertension. Circulation 1990; 82 (Suppl.11): 29.

10. Yurenev A.P. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: Multicentral trial. Am J Hypertens 1992; 5: 182-189.

11. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham study. Am J Hy-pert 2000; 13: S3-S10.

12. Muiesan M.L., Salvetti M., Rizzoni D. et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. Hypertension 1995; 13:1091-1097.

13. Kobalava Zh.D., Kotovskaja Ju.V. Hypertension and atherosclerosis: principal results of the ELSA study. Serdce 2002; 3:1–6. Russian (Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония и атеросклероз: основные результаты исследования ELSA. Сердце 2002; 3:1–6).

14. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;.359:995-1003.

15. Hoogwerf B.J., Young J.B. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 2000; 67(4):287-93.

16. The price list for medical services. KOGUZ “Kirov Regional Hospital” from 23.01.2009. Russian (Прейскурант на медицинские услуги. КОГУЗ "Кировская областная клиническая больница от

17. 01.2009).

18. Zethraeus N., Ben Sedrine W., Caulin F. et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int. 2002; 13(11):841-57.

19. Kanis J.A., Dawson A., Oden A. et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos. Int. 2001; 12(5):356-61.

20. Karpov Ju.A., Chazova I.E., Vigdorchik A.V on behalf of the research team. Efficacy and safety of a fixed combination of amlodipine and valsartan in the treatment of hypertension in clinical practice: results of the Russian observational study EXTRA-2. Sistemnye gipertenzii 2010; 4: 14-20. Russian (Карпов Ю.А., Чазова И.Е., Вигдорчик А.В., от лица исследовательской группы. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертензии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии 2010; 4: 14-20).

21. Klingbeil A.U. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.

For citation:

Tarlovskaya E.I., Maksimchuk N.S., Malchicova S.V., Avksentieva M.V., Sapozhnikova I.E., Balandina Y.A. ECONOMIC BENEFITS OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2011;7(5):543-548. (In Russ.)

Views: 374

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)